View Item 

Show simple item record

A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares
dc.contributor.authorSaag, Kenneth G.
dc.contributor.authorKhanna, Puja P.
dc.contributor.authorKeenan, Robert T.
dc.contributor.authorOhlman, Sven
dc.contributor.authorOsterling Koskinen, Lisa
dc.contributor.authorSparve, Erik
dc.contributor.authorÅkerblad, Ann‐charlotte
dc.contributor.authorWikén, Margareta
dc.contributor.authorSo, Alexander
dc.contributor.authorPillinger, Michael H.
dc.contributor.authorTerkeltaub, Robert
dc.date.accessioned2021-08-03T18:17:41Z
dc.date.available2022-09-03 14:17:39en
dc.date.available2021-08-03T18:17:41Z
dc.date.issued2021-08
dc.identifier.citationSaag, Kenneth G.; Khanna, Puja P.; Keenan, Robert T.; Ohlman, Sven; Osterling Koskinen, Lisa; Sparve, Erik; Åkerblad, Ann‐charlotte ; Wikén, Margareta ; So, Alexander; Pillinger, Michael H.; Terkeltaub, Robert (2021). "A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares." Arthritis & Rheumatology (8): 1533-1542.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/168527
dc.publisherSobi
dc.publisherWiley Periodicals, Inc.
dc.titleA Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168527/1/art41699.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168527/2/art41699_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168527/3/art41699-sup-0009-Methods.pdf
dc.identifier.doi10.1002/art.41699
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferenceMitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD, et al. Rilonacept for gout flare prevention during initiation of uric acid- lowering therapy: results from the PRESURGE- 2 international, phase 3, randomized, placebo- controlled trial. Rheumatology (Oxford) 2013; 52: 1285 - 92.
dc.identifier.citedreferenceTran AP, Edelman J. Interleukin- 1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 2011; 14: e33 - 7.
dc.identifier.citedreferenceHirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ. Efficacy of canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis- related health outcomes measures. Int J Clin Pract 2014; 68: 1503 - 7.
dc.identifier.citedreferenceSchlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active- controlled, double- blind trials and their initial extensions. Ann Rheum Dis 2012; 71: 1839 - 48.
dc.identifier.citedreferenceSchlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health- related quality of life in patients with difficult- to- treat gouty arthritis by suppressing inflammation: results of a randomized, dose- ranging study. Arthritis Res Ther 2011; 13: R53.
dc.identifier.citedreferenceSchlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double- blind, randomised study. Ann Rheum Dis 2011; 70: 1264 - 71.
dc.identifier.citedreferenceSo A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult- to- treat gouty arthritis: results of a multicenter, phase II, dose- ranging study. Arthritis Rheum 2010; 62: 3064 - 76.
dc.identifier.citedreferenceSolomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin- 1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann Intern Med 2018; 169: 535 - 42.
dc.identifier.citedreferenceAouba A, Deshayes S, Frenzel L, Decottignies A, Pressiat C, Bienvenu B, et al. Efficacy of anakinra for various types of crystal- induced arthritis in complex hospitalized patients: a case series and review of the literature. Mediators Inflamm 2015; 2015: 792173.
dc.identifier.citedreferenceGhosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 2013; 65: 1381 - 4.
dc.identifier.citedreferenceOttaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 2013; 15: R123.
dc.identifier.citedreferenceSo A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL- 1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28.
dc.identifier.citedreferencePascart T, Norberciak L, Ea HK, Graf S, Guggenbuhl P, Liote F. Difficult- to- treat gout flares: eligibility for interleukin- 1 inhibition in private practice is uncommon according to current EMA approval. Rheumatology (Oxford) 2019; 58: 2181 - 7.
dc.identifier.citedreferenceFitzGerald JD, Dalbeth N, Mikuls T, Brignardello- Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol 2020; 72: 879 - 95.
dc.identifier.citedreferenceJanssen CA, Oude Voshaar MA, Vonkeman HE, Jansen T, Janssen M, Kok MR, et al. Anakinra for the treatment of acute gout flares: a randomized, double- blind, placebo- controlled, active- comparator, non- inferiority trial. Rheumatology (Oxford) 2019; 58: 1344 - 52.
dc.identifier.citedreferenceSchumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, et al. Rilonacept (interleukin- 1 trap) for prevention of gout flares during initiation of uric acid- lowering therapy: results from a phase III randomized, double- blind, placebo- controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 2012; 64: 1462 - 70.
dc.identifier.citedreferenceSchumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al. Rilonacept (interleukin- 1 trap) in the prevention of acute gout flares during initiation of urate- lowering therapy: results of a phase II randomized, double- blind, placebo- controlled trial. Arthritis Rheum 2012; 64: 876 - 84.
dc.identifier.citedreferenceTerkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo- controlled, monosequence crossover, non- randomised, single- blind pilot study. Ann Rheum Dis 2009; 68: 1613 - 7.
dc.identifier.citedreferenceTerkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013; 15: R25.
dc.identifier.citedreferenceNeogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative [published erratum appears in Arthritis Rheumatol 2016;68:515]. Arthritis Rheumatol 2015; 67: 2557 - 68.
dc.identifier.citedreferenceCohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin- 1 receptor antagonist, in combination with methotrexate: results of a twenty- four- week, multicenter, randomized, double- blind, placebo- controlled trial. Arthritis Rheum 2002; 46: 614 - 24.
dc.identifier.citedreferenceFleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1006 - 12.
dc.identifier.citedreferenceWiken M, Hallen B, Kullenberg T, Koskinen LO. Development and effect of antibodies to anakinra during treatment of severe CAPS: sub- analysis of a long- term safety and efficacy study. Clin Rheumatol 2018; 37: 3381 - 6.
dc.identifier.citedreferenceKineret (anakinra) prescribing information. Stockholm (Sweden): Sobi; 2001. URL: https://wwwaccessdatafdagov/drugsatfda_docs/label/2012/103950s5136lblpdf.
dc.identifier.citedreferenceSingh JA, Taylor WJ, Dalbeth N, Simon LS, Sundy J, Grainger R, et al. OMERACT endorsement of measures of outcome for studies of acute gout. J Rheumatol 2014; 41: 569 - 73.
dc.identifier.citedreferenceJanssen CA, Voshaar MA, Klooster PM, Vonkeman HE, van de Laar M. Development and validation of a patient- reported gout attack intensity score for use in gout clinical studies. Rheumatology (Oxford) 2019; 58: 1928 - 34.
dc.identifier.citedreferenceKhanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447 - 61.
dc.identifier.citedreferenceRichette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 updated European League Against Rheumatism evidence- based recommendations for the diagnosis of gout. Ann Rheum Dis 2020; 79: 31 - 8.
dc.identifier.citedreferenceChen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra- s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010; 40: 210 - 4.
dc.identifier.citedreferenceGratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid- sparing agent for gout inflammation. Arthritis Rheum 2009; 61: 1268 - 70.
dc.identifier.citedreferenceKeenan RT, O- Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011; 124: 155 - 63.
dc.identifier.citedreferenceThueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum 2015; 45: 81 - 5.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art41699.pdf
Size:
768.5KB
Format:
PDF
View/Open
Name:
art41699_am.pdf
Size:
306.8KB
Format:
PDF
View/Open
Name:
art41699-sup-0009-Methods.pdf
Size:
1.380MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.